1ABT Stock Overview

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. More details

1ABT fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	6/6
Financial Health	6/6
Dividends	4/6

Rewards

Revenue is forecast to grow 6.92% per year

Earnings grew by 139.9% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 10.1% per year for the next 3 years

Shares are highly illiquid

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Abbott Laboratories Competitors

Price History & Performance

Summary of share price highs, lows and changes for Abbott Laboratories
Historical stock prices
Current Share Price	US$115.42
52 Week High	US$120.94
52 Week Low	US$117.96
Beta	0.74
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	1.30%

Recent updates

Shareholder Returns

	1ABT	IT Medical Equipment	IT Market
7D	-4.0%	-4.3%	-2.3%
1Y	n/a	-6.5%	14.2%

Return vs Industry: Insufficient data to determine how 1ABT performed against the Italian Medical Equipment industry.

Return vs Market: Insufficient data to determine how 1ABT performed against the Italian Market.

Price Volatility

Is 1ABT's price volatile compared to industry and market?
1ABT volatility
1ABT Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.6%
Market Average Movement	5.5%
10% most volatile stocks in IT Market	8.7%
10% least volatile stocks in IT Market	3.4%

Stable Share Price: 1ABT's share price has been volatile over the past 3 months compared to the Italian market.

Volatility Over Time: Insufficient data to determine 1ABT's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1888	114,000	Robert Ford	www.abbott.com

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.

Abbott Laboratories Fundamentals Summary

How do Abbott Laboratories's earnings and revenue compare to its market cap?
1ABT fundamental statistics
Market cap	€201.10b
Earnings (TTM)	€11.84b
Revenue (TTM)	€37.28b

17.0x

P/E Ratio

5.4x

P/S Ratio

Is 1ABT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1ABT income statement (TTM)
Revenue	US$42.34b
Cost of Revenue	US$18.64b
Gross Profit	US$23.71b
Other Expenses	US$10.26b
Earnings	US$13.45b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	7.73
Gross Margin	55.99%
Net Profit Margin	31.77%
Debt/Equity Ratio	27.1%

How did 1ABT perform over the long term?

See historical performance and comparison

Dividends

1.8%

Current Dividend Yield

29%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/25 10:36
End of Day Share Price	2025/05/23 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Abbott Laboratories is covered by 62 analysts. 26 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
David Toung	Argus Research Company
Stephan Gasteyger	Atlantic Equities LLP
Ishan Majumdar	Baptista Research

Abbott Laboratories BIT:1ABT Stock Report